Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced on February 27 that the US Food and Drug Administration approved three new indications for once-weekly Sogroya injection 5 mg, 10 mg, or 15 mg, a long-acting growth hormone, for children aged at least 2.5 years with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age without catch-up growth by the age of 2 years, and growth failure associated with Noonan Syndrome.

The approval marks the first long-acting growth hormone supporting children with these three indications in the United States. Somapacitan-beco also holds approval for children aged at least 2.5 years with growth hormone deficiency. Since the option is once-weekly, it helps children and caregivers struggling with daily injections for hormone treatment.

In another development, Novo Nordisk A/S (NYSE:NVO) and Vivtex Corporation announced on February 25 a partnership for the development of next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. According to the terms of the agreement, Vivtex would license select oral drug-delivery technologies to Novo Nordisk A/S (NYSE:NVO), with Vivtex eligible to receive upfront consideration, research funding, and milestone payments totalling up to $2.1 billion, and tiered royalties on future product sales.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.